An open-label study of aripiprazole in children with a bipolar disorder

Robert L Findling, Nora K. McNamara, Eric A. Youngstrom, Robert J. Stansbrey, Thomas W. Frazier, Jacqui Lingler, Benjamin D. Otto, Christine A. Demeter, Brieana M. Rowles, Joseph R. Calabrese

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R 50. Results: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p <0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.

Original languageEnglish (US)
Pages (from-to)345-351
Number of pages7
JournalJournal of Child and Adolescent Psychopharmacology
Volume21
Issue number4
DOIs
StatePublished - Aug 1 2011
Externally publishedYes

Fingerprint

Bipolar Disorder
Depression
Psychomotor Agitation
Epistaxis
Aripiprazole
Appetite
Diagnostic and Statistical Manual of Mental Disorders
Weight Gain
Headache
Outpatients
Therapeutics
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health

Cite this

Findling, R. L., McNamara, N. K., Youngstrom, E. A., Stansbrey, R. J., Frazier, T. W., Lingler, J., ... Calabrese, J. R. (2011). An open-label study of aripiprazole in children with a bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 21(4), 345-351. https://doi.org/10.1089/cap.2010.0102

An open-label study of aripiprazole in children with a bipolar disorder. / Findling, Robert L; McNamara, Nora K.; Youngstrom, Eric A.; Stansbrey, Robert J.; Frazier, Thomas W.; Lingler, Jacqui; Otto, Benjamin D.; Demeter, Christine A.; Rowles, Brieana M.; Calabrese, Joseph R.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 21, No. 4, 01.08.2011, p. 345-351.

Research output: Contribution to journalArticle

Findling, RL, McNamara, NK, Youngstrom, EA, Stansbrey, RJ, Frazier, TW, Lingler, J, Otto, BD, Demeter, CA, Rowles, BM & Calabrese, JR 2011, 'An open-label study of aripiprazole in children with a bipolar disorder', Journal of Child and Adolescent Psychopharmacology, vol. 21, no. 4, pp. 345-351. https://doi.org/10.1089/cap.2010.0102
Findling, Robert L ; McNamara, Nora K. ; Youngstrom, Eric A. ; Stansbrey, Robert J. ; Frazier, Thomas W. ; Lingler, Jacqui ; Otto, Benjamin D. ; Demeter, Christine A. ; Rowles, Brieana M. ; Calabrese, Joseph R. / An open-label study of aripiprazole in children with a bipolar disorder. In: Journal of Child and Adolescent Psychopharmacology. 2011 ; Vol. 21, No. 4. pp. 345-351.
@article{4b0c012a26a842df80d52bff9d2a4582,
title = "An open-label study of aripiprazole in children with a bipolar disorder",
abstract = "Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R 50. Results: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p <0.001) were noted at the end of study participation. Sixty of the subjects (62.5{\%}) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.",
author = "Findling, {Robert L} and McNamara, {Nora K.} and Youngstrom, {Eric A.} and Stansbrey, {Robert J.} and Frazier, {Thomas W.} and Jacqui Lingler and Otto, {Benjamin D.} and Demeter, {Christine A.} and Rowles, {Brieana M.} and Calabrese, {Joseph R.}",
year = "2011",
month = "8",
day = "1",
doi = "10.1089/cap.2010.0102",
language = "English (US)",
volume = "21",
pages = "345--351",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - An open-label study of aripiprazole in children with a bipolar disorder

AU - Findling, Robert L

AU - McNamara, Nora K.

AU - Youngstrom, Eric A.

AU - Stansbrey, Robert J.

AU - Frazier, Thomas W.

AU - Lingler, Jacqui

AU - Otto, Benjamin D.

AU - Demeter, Christine A.

AU - Rowles, Brieana M.

AU - Calabrese, Joseph R.

PY - 2011/8/1

Y1 - 2011/8/1

N2 - Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R 50. Results: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p <0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.

AB - Objective: The purpose of this open-label study was to describe the effectiveness of aripiprazole (APZ) in the treatment of children with bipolar disorders suffering from manic symptomatology. Method: Symptomatic outpatients (Young Mania Rating Scale [YMRS] score ≥15) meeting strict, unmodified, Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic symptom criteria for a bipolar disorder, ages 4-9 years, were eligible. Subjects were treated prospectively with flexible doses of APZ (maximum daily dose of 15 mg/day), for up to 16 weeks or until a priori response criteria were met. Outcome measures included the YMRS, Clinical Global Impressions Scale-Severity, Children's Global Assessment Scale (CGAS), and the Children's Depression Rating Scale-Revised (CDRS-R). A priori response criteria consisted of 3 of 4 consecutive weeks with (1) CDRS-R 50. Results: Ninety-six children (62 males; mean age of 6.9 (SD = 1.7), received APZ for an average length of treatment of 12.5 (SD = 3.9) weeks. Significant improvements in YMRS, CDRS-R, CGAS, and Clinical Global Impressions Scale-Severity scores (p <0.001) were noted at the end of study participation. Sixty of the subjects (62.5%) met a priori response criteria at study's end. The most common side effects noted were stomachache, increased appetite, and headache. Two subjects were removed from the study due to side effects [epistaxis (n = 1); akathisia (n = 1)]. Subjects experienced an average weight gain of 2.4 (SD = 1.9) kg. Conclusion: APZ may be effective in the acute treatment of symptoms of children with bipolar illnesses.

UR - http://www.scopus.com/inward/record.url?scp=80052102832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052102832&partnerID=8YFLogxK

U2 - 10.1089/cap.2010.0102

DO - 10.1089/cap.2010.0102

M3 - Article

C2 - 21823912

AN - SCOPUS:80052102832

VL - 21

SP - 345

EP - 351

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 4

ER -